Agilon Health’s (AGL) Neutral Rating Reiterated at BTIG Research

Agilon Health (NYSE:AGL)‘s stock had its “neutral” rating reissued by research analysts at BTIG Research in a research note issued on Friday,Benzinga reports.

AGL has been the topic of several other research reports. Royal Bank Of Canada raised Agilon Health from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, December 3rd. Sanford C. Bernstein reiterated a “market perform” rating and set a $1.40 price objective (down previously from $4.00) on shares of Agilon Health in a research report on Wednesday, August 20th. Jefferies Financial Group lowered their target price on shares of Agilon Health from $2.40 to $1.10 and set a “hold” rating for the company in a report on Friday, August 15th. Wells Fargo & Company dropped their price target on shares of Agilon Health from $1.50 to $1.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, Zacks Research raised shares of Agilon Health from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 21st. Four investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Agilon Health has a consensus rating of “Hold” and a consensus target price of $2.73.

Agilon Health Stock Down 0.2%

Agilon Health stock opened at $0.72 on Friday. The company’s 50-day moving average price is $0.77 and its 200-day moving average price is $1.36. The company has a market cap of $298.08 million, a PE ratio of -0.96 and a beta of 0.07. Agilon Health has a twelve month low of $0.51 and a twelve month high of $6.08.

Agilon Health (NYSE:AGL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.09). Agilon Health had a negative return on equity of 75.92% and a negative net margin of 5.24%.The company had revenue of $1.44 billion during the quarter, compared to analysts’ expectations of $1.43 billion. As a group, sell-side analysts expect that Agilon Health will post -0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agilon Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Gabelli Funds LLC purchased a new stake in Agilon Health in the 1st quarter valued at about $48,000. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in shares of Agilon Health during the second quarter valued at approximately $31,000. 111 Capital bought a new stake in shares of Agilon Health during the second quarter valued at approximately $36,000. Acropolis Investment Management LLC purchased a new stake in shares of Agilon Health in the second quarter valued at approximately $44,000. Finally, Wealthcare Advisory Partners LLC bought a new position in Agilon Health in the third quarter worth approximately $26,000.

Agilon Health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.